MYGN Myriad Genetics: Total Company Value-to-Revenue Ratio

myriad.com (MYGN) - corporate logo

Myriad Genetics, Inc. (MYGN) maintains stable cash flows based on the high demand for genetic testing. The historical EV/Sales trend demonstrates the current enterprise value, where the 788.59 metric determines the parameter status. This price action confirms a portfolio expansion into mental health, although the risk of reagent supply disruptions due to geopolitics remains a significant factor.

Myriad Genetics (MYGN) Company Value to Revenue: for the period 11/23/2025 - 11/20/2026

Myriad - analytical breakdowns and key metrics (MYGN)

- market price and analyst price targets:
- company stock capitalization data:
Fundamental company valuation:MYGN - Myriad Genetics, Inc.
Product sample of Myriad Genetics Corp

This indicator compares the total enterprise value to annual revenue, eliminating the impact of leverage on the valuation. By analyzing the EV/Sales multiple, an investor determines the actual market value of assets per unit of revenue. The metric confirms operational efficiency and the stability of cash flows. For Myriad Genetics, Inc. (MYGN), this reflects the capitalization of innovations in molecular diagnostics. The implementation of AI models and the updating of the test portfolio should fundamentally reprice this ratio.